

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4638455/publications.pdf>

Version: 2024-02-01

172  
papers

4,578  
citations

94433

37  
h-index

138484

58  
g-index

175  
all docs

175  
docs citations

175  
times ranked

5850  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5972-5982.	7.0	231
2	Circulating microRNAs in plasma as early detection markers for breast cancer. <i>International Journal of Cancer</i> , 2013, 132, 1602-1612.	5.1	227
3	Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 353-362.	4.2	196
4	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 734.	2.6	126
5	Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. <i>Annals of Oncology</i> , 2020, 31, 61-71.	1.2	119
6	Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e76729.	2.5	112
7	First international consensus conference on standardization of oncoplastic breast conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 139-149.	2.5	99
8	A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. <i>Annals of Surgery</i> , 2022, 276, e553-e562.	4.2	95
9	Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database. <i>European Journal of Cancer</i> , 2012, 48, 1947-1956.	2.8	84
10	Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?. <i>Annals of Surgical Oncology</i> , 2016, 23, 789-795.	1.5	84
11	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 523-537.	2.5	84
12	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. <i>British Journal of Cancer</i> , 2015, 113, 1565-1570.	6.4	83
13	Evaluation of Virtual Touch Tissue Imaging Quantification, a New Shear Wave Velocity Imaging Method, for Breast Lesion Assessment by Ultrasound. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	77
14	Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1118-1127.	1.5	77
15	Recommendations for the aesthetic evaluation of breast cancer conservative treatment. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 629-637.	2.5	76
16	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. <i>BMC Cancer</i> , 2015, 15, 403.	2.6	70
17	Interobserver reliability of automated breast volume scanner (ABVS) interpretation and agreement of ABVS findings with hand held breast ultrasound (HHUS), mammography and pathology results. <i>European Journal of Radiology</i> , 2013, 82, e332-e336.	2.6	66
18	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. <i>BMC Cancer</i> , 2014, 14, 512.	2.6	65

#	ARTICLE	IF	CITATIONS
19	Normal breast tissue stiffness measured by a new ultrasound technique: Virtual touch tissue imaging quantification (VTIQ). <i>European Journal of Radiology</i> , 2013, 82, e676-e679.	2.6	61
20	Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?. <i>European Journal of Cancer</i> , 2016, 69, 142-150.	2.8	59
21	Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials. <i>Annals of Surgical Oncology</i> , 2017, 24, 2855-2862.	1.5	57
22	Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 491-499.	2.5	54
23	Aesthetic and functional results after breast conserving surgery as correlates of quality of life measured by a German version of the Breast Cancer Treatment Outcome Scale (BCTOS). <i>Breast</i> , 2010, 19, 470-474.	2.2	52
24	Do Reexcisions Impair Aesthetic Outcome in Breast Conservation Surgery? Exploratory Analysis of a Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 541-547.	1.5	51
25	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 214-227.	1.4	51
26	A plasma metabolite panel as biomarkers for early primary breast cancer detection. <i>International Journal of Cancer</i> , 2019, 144, 2833-2842.	5.1	50
27	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	10.7	49
28	Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. <i>Breast</i> , 2013, 22, 537-542.	2.2	48
29	Long-term objective esthetic outcome after breast-conserving therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 345-351.	2.5	46
30	Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy. <i>European Journal of Surgical Oncology</i> , 2011, 37, 116-121.	1.0	45
31	Aesthetics in Breast Conserving Therapy: Do Objectively Measured Results Match Patients'™ Evaluations?. <i>Annals of Surgical Oncology</i> , 2011, 18, 134-138.	1.5	45
32	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	2.5	45
33	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. <i>European Journal of Cancer</i> , 2021, 143, 134-146.	2.8	44
34	Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. <i>Breast</i> , 2012, 21, 303-308.	2.2	42
35	Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1053-1060.	4.2	42
36	Evaluation of an automated breast 3D-ultrasound system by comparing it with hand-held ultrasound (HHUS) and mammography. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 889-895.	1.7	41

#	ARTICLE	IF	CITATIONS
37	The association between breast cancer and S100P methylation in peripheral blood by multicenter caseâ€control studies. <i>Carcinogenesis</i> , 2017, 38, 312-320.	2.8	41
38	COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 135-143.	2.5	41
39	Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. <i>Oncolmunology</i> , 2016, 5, e1057387.	4.6	38
40	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. <i>Annals of Surgery</i> , 2022, 275, 576-581.	4.2	38
41	Objective assessment of aesthetic outcome after breast conserving therapy: Subjective third party panel rating and objective BCCT.core software evaluation. <i>Breast</i> , 2012, 21, 61-65.	2.2	36
42	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	1.4	35
43	Predictors of early poor aesthetic outcome after breast-conserving surgery in patients with breast cancer: Initial results of a prospective cohort study at a single institution. <i>Journal of Surgical Oncology</i> , 2014, 110, 801-806.	1.7	34
44	DEGUM Recommendations on Infection Prevention in Ultrasound andÂEndoscopic Ultrasound. <i>Ultraschall in Der Medizin</i> , 2018, 39, 284-303.	1.5	34
45	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology</i> , The, 2020, 21, e375-e385.	10.7	34
46	Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. <i>Oncotarget</i> , 2017, 8, 54537-54547.	1.8	34
47	DNA methylation array analysis identifies breast cancer associated <i>RPTOR</i> , <i>MGRN1</i> and <i>RAPSN</i> hypomethylation in peripheral blood DNA. <i>Oncotarget</i> , 2016, 7, 64191-64202.	1.8	33
48	Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1744-1751.	1.5	33
49	RESPONDER â€ diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. <i>BMC Cancer</i> , 2018, 18, 851.	2.6	32
50	Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI?. <i>Annals of Oncology</i> , 2012, 23, 98-104.	1.2	31
51	Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer. <i>International Journal of Cancer</i> , 2016, 138, 2499-2509.	5.1	31
52	Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. <i>Journal of Clinical Oncology</i> , 2022, 40, 1903-1915.	1.6	31
53	Time trends (2006â€2015) of quality indicators in EUSOMA-certified breast centres. <i>European Journal of Cancer</i> , 2017, 85, 15-22.	2.8	30
54	Refining scores based on patient reported outcomes â€ statistical and medical perspectives. <i>BMC Medical Research Methodology</i> , 2019, 19, 167.	3.1	30

#	ARTICLE	IF	CITATIONS
55	Simultaneous integrated boost for adjuvant treatment of breast cancer- intensity modulated vs. conventional radiotherapy: The IMRT-MC2 trial. <i>BMC Cancer</i> , 2011, 11, 249.	2.6	29
56	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019, 26, 3892-3901.	1.5	29
57	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2222-2231.	2.5	27
58	Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 219-224.	1.4	27
59	Time trends of neoadjuvant chemotherapy for early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 3049-3058.	5.1	26
60	Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1831-1837.	1.5	25
61	Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice. <i>Breast</i> , 2019, 45, 89-96.	2.2	25
62	Does a Supplementary Preoperative Breast MRI in Patients with Invasive Lobular Breast Cancer Change Primary and Secondary Surgical Interventions?. <i>Annals of Surgical Oncology</i> , 2011, 18, 2143-2149.	1.5	24
63	Prognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up Study. <i>Annals of Surgical Oncology</i> , 2013, 20, 1865-1871.	1.5	24
64	Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 289-299.	2.5	23
65	Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients. <i>European Journal of Radiology</i> , 2021, 135, 109468.	2.6	23
66	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22
67	Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis. <i>European Radiology</i> , 2018, 28, 2499-2506.	4.5	21
68	Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 429-438.	2.5	21
69	The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics – An international, multicentre trial. <i>European Journal of Cancer</i> , 2022, 161, 1-9.	2.8	21
70	Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers. <i>Acta Oncologica</i> , 2016, 55, 712-719.	1.8	20
71	Clinical Validation of the BREAST-Q Breast-Conserving Therapy Module. <i>Annals of Surgical Oncology</i> , 2019, 26, 2759-2767.	1.5	20
72	Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 683-693.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Breast Cancer Mastectomy Trends Between 2006 and 2010: Association with Magnetic Resonance Imaging, Immediate Breast Reconstruction, and Hospital Volume. <i>Annals of Surgical Oncology</i> , 2013, 20, 3839-3846.	1.5	19
74	Fluctuating Mastectomy Rates Across Time and Geography. <i>Annals of Surgical Oncology</i> , 2013, 20, 2114-2116.	1.5	19
75	Is Mastectomy Oncologically Safer than Breast-Conserving Treatment in Early Breast Cancer. <i>Breast Care</i> , 2017, 12, 385-390.	1.4	19
76	Retrospective, Multicenter Analysis Comparing Conventional with Oncoplastic Breast Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 1061-1070.	1.5	19
77	Plasma S100P level as a novel prognostic marker of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 329-338.	2.5	18
78	Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. <i>International Journal of Molecular Sciences</i> , 2018, 19, 900.	4.1	18
79	Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype. <i>Annals of Surgical Oncology</i> , 2019, 26, 4381-4389.	1.5	18
80	Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6407.	4.1	18
81	Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1490-1498.	1.6	16
82	Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 425-433.	2.5	16
83	Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 757-766.	1.5	15
84	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 312-319.	0.9	15
85	Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 2435-2443.	1.5	15
86	Contrast of Digital and Health Literacy Between IT and Health Care Specialists Highlights the Importance of Multidisciplinary Teams for Digital Health – A Pilot Study. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 734-745.	2.1	15
87	Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 1076-1084.	1.5	15
88	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	5.0	14
89	Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?. <i>European Journal of Radiology</i> , 2020, 128, 109025.	2.6	14
90	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. <i>Radiation Oncology</i> , 2020, 15, 235.	2.7	13

#	ARTICLE	IF	CITATIONS
91	De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment. <i>Lancet Oncology</i> , The, 2021, 22, 435-436.	10.7	13
92	Predictors of Residual Tumor in Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 451-458.	1.5	12
93	Development and psychometric validation of a shorter version of the Breast Cancer Treatment Outcome Scale (BCTOS-12). <i>Breast</i> , 2018, 38, 58-65.	2.2	12
94	Long-Term Patient Satisfaction and Quality of Life After Breast-Conserving Therapy: A Prospective Study Using the BREAST-Q. <i>Annals of Surgical Oncology</i> , 2021, 28, 8742-8751.	1.5	12
95	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	3.7	12
96	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , 2021, 11, e045239.	1.9	12
97	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. <i>Breast Care</i> , 2012, 7, 364-369.	1.4	11
98	A New Practical Decision Rule to Better Differentiate <sc>Blâ€RADS</sc> 3 or 4 Breast Masses on Breast Ultrasound. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 427-436.	1.7	11
99	The Potential of Shear Wave Elastography to Reduce Unnecessary Biopsies in Breast Cancer Diagnosis: An International, Diagnostic, Multicenter Trial. <i>Ultraschall in Der Medizin</i> , 2023, 44, 162-168.	1.5	11
100	Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1011-1018.	1.7	10
101	The Collagenase of the Bacterium <i>Clostridium histolyticum</i> in the Treatment of Irradiation-Induced Capsular Contracture. <i>Aesthetic Plastic Surgery</i> , 2019, 43, 836-844.	0.9	10
102	De-escalation towards omission is the tipping point of individualizing breast cancer surgery. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1543-1545.	1.0	10
103	Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1451-1458.	1.7	9
104	Inter-rater reliability and double reading analysis of an automated three-dimensional breast ultrasound system: comparison of two independent examiners. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 571-582.	1.7	9
105	IgG4â€related sclerosing mastitis in a 49â€yearâ€old patient with multiple, tumorâ€like nodulesâ€”Diagnostic accuracy of core needle biopsy. <i>Breast Journal</i> , 2019, 25, 1251-1253.	1.0	9
106	Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patientsâ€”First Clinical Results From a Single Center. <i>Frontiers in Oncology</i> , 2019, 9, 384.	2.8	9
107	International development and implementation of a core measurement set for research and audit studies in implant-based breast reconstruction: a study protocol. <i>BMJ Open</i> , 2020, 10, e035505.	1.9	9
108	Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States. <i>Cancers</i> , 2020, 12, 2419.	3.7	9



#	ARTICLE	IF	CITATIONS
109	Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 451-460.	2.5	8
110	Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up—a case—control study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 443-447.	1.7	8
111	Evaluation of the FUSION-X-US-II prototype to combine automated breast ultrasound and tomosynthesis. <i>European Radiology</i> , 2021, 31, 3712-3720.	4.5	8
112	The importance of multi-modal imaging and clinical information for humans and AI-based algorithms to classify breast masses (INSPIRED 003): an international, multicenter analysis. <i>European Radiology</i> , 2022, 32, 4101-4115.	4.5	8
113	Predictors of resectability in breast-conserving therapy. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1023-1031.	1.7	7
114	Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4173-4180.	2.0	7
115	Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 457-467.	2.5	7
116	Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A—Type Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 848-859.	3.0	7
117	Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 165-176.	0.6	7
118	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. <i>Journal of Medical Genetics</i> , 2011, 48, 698-702.	3.2	5
119	LECANDUS study (LEsion CANDidate Detection in UltraSound Data): evaluation of image analysis algorithms for breast lesion detection in volume ultrasound data. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 423-428.	1.7	5
120	Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 123-129.	1.7	5
121	Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS—EG score. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 437-446.	2.5	5
122	Psychometric validation of the Breast Cancer Treatment Outcome Scale (BCTOS-12): a prospective cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1679-1686.	1.7	5
123	Exam preparatory course for the 2nd part of the German medical examination in obstetrics and gynecology—a potential tool for the recruitment of new residents during the occupational decision process before the practical year?. <i>BMC Medical Education</i> , 2019, 19, 24.	2.4	5
124	Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index. <i>PLoS ONE</i> , 2019, 14, e0211337.	2.5	5
125	Oncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast surgeons. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1109-1114.	1.7	5
126	Patients should be the tipping point of individualizing breast cancer surgery: Commentary on —Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges—. <i>Annals of Oncology</i> , 2020, 31, 1264.	1.2	5



#	ARTICLE	IF	CITATIONS
127	Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). <i>Radiation Oncology</i> , 2020, 15, 134.	2.7	5
128	uPA–PAI–1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. <i>EMBO Molecular Medicine</i> , 2021, 13, e13110.	6.9	5
129	Breast and axillary surgery after neoadjuvant systemic treatment – A review of clinical routine recommendations and the latest clinical research. <i>Breast</i> , 2022, 62, S7-S11.	2.2	5
130	Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 401-411.	4.2	4
131	Exam preparation course in obstetrics and gynecology for the German Medical State Examination: proof of concept and implications for the recruitment of future residents. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1235-1241.	1.7	4
132	Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 971-978.	1.7	4
133	Standards of hygiene for ultrasound-guided core cut biopsies of the breast. <i>Ultraschall in Der Medizin</i> , 2018, 39, 636-642.	1.5	4
134	Response Prediction to Neoadjuvant Systemic Treatment in Breast Cancer – Yet Another Algorithm?. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 654-655.	2.1	4
135	Parity improves anti-tumor immunity in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 104981-104991.	1.8	4
136	Re: Measuring Surgery-Specific Aspects of Quality of Life in Oncologic Breast Surgery-Measuring Aesthetic and Functional Outcome Using the BCTOS (Breast Cancer Treatment Outcome Scale). <i>Breast Journal</i> , 2011, 17, 441-442.	1.0	3
137	Detected, yet not Diagnosed – Breast Cancer Screening with MRI Mammography in High-Risk Women. <i>Breast Care</i> , 2012, 7, 236-239.	1.4	3
138	Recall management of patients with Rofil Medical breast implants. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 939-945.	1.0	3
139	Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 145-152.	1.7	3
140	Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 268, e60-e61.	4.2	3
141	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. <i>Breast Care</i> , 2018, 13, 440-446.	1.4	3
142	Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 627-636.	2.5	3
143	Artificial intelligence to accurately identify breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: An international multicenter analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 565-565.	1.6	3
144	Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 1079-1085.	1.7	2

#	ARTICLE	IF	CITATIONS
145	Detection and Removal of Ceramic Clip Markers from Breast Tissue by Ultrasound-Guided, Vacuum-Assisted Minimally Invasive Biopsy in a Turkey Breast Model. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 341-345.	1.5	2
146	Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 48-53.	1.8	2
147	Do hospital type or caseload make a difference in chemotherapy treatment patterns for early breast cancer? Results from 104 German institutions, 2008â€“2017. <i>Breast</i> , 2021, 58, 63-71.	2.2	2
148	Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 589-598.	2.5	2
149	Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature. <i>Breast Care</i> , 2011, 6, 395-398.	1.4	1
150	Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 725-734.	2.5	1
151	Do Contralateral Prophylactic Mastectomies Help Patients?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4191-4191.	1.6	1
152	ASO Author Reflections: The BREAST-Q BCT Module and Its Use in Clinical Practice. <i>Annals of Surgical Oncology</i> , 2019, 26, 788-789.	1.5	1
153	Adjuvant Radiation Therapy for Male Breast Cancerâ€”A Rare Indication?. <i>Cancers</i> , 2020, 12, 3645.	3.7	1
154	Surgeonâ€™s preference of subcutaneous tissue resection: most important factor for short-term complications in subcutaneous implant placement after mastectomyâ€”results of a cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1037-1045.	1.7	1
155	Measurement and Optimizing Cosmetic Outcomes for Breast Excisions/Factors Influencing Aesthetic Outcomes of Breast Conservation Surgery. , 2020, , 93-106.		1
156	COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 525-525.	1.6	1
157	Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSC) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 555-555.	1.6	1
158	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , 2021, 11, e045239.	1.9	1
159	Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patientsâ€™ and Physiciansâ€™ Assessment from the Randomized IMRT-MC2 Trial. <i>Cancers</i> , 2022, 14, 3010.	3.7	1
160	Quality of life and anxiety of patients affected by the PIP/Rofil Medical breast implant recall: results from a prospective monocentre cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 957-962.	1.7	0
161	Reply to Comment on â€”Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniquesâ€™. <i>British Journal of Cancer</i> , 2016, 114, e4-e4.	6.4	0
162	Investigation of Global Methylation in Peripheral Blood from Breast Cancer Patients. <i>Journal of Molecular Biomarkers &amp; Diagnosis</i> , 2017, 01, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	First proof-of-concept evaluation of the FUSION-X-US-II prototype for the performance of automated breast ultrasound in healthy volunteers. Archives of Gynecology and Obstetrics, 2021, 304, 559-566.	1.7	0
164	ASO Visual Abstract: Long-Term Patient Satisfaction and Quality of Life after Breast-Conserving Therapy – A Prospective Study Using the BREAST-Q. Annals of Surgical Oncology, 2021, 28, 583-583.	1.5	0
165	ASO Visual Abstract: Retrospective Multicenter Analysis Comparing Conventional with Oncoplastic Breast-Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. Annals of Surgical Oncology, 2022, 29, 1073-1075.	1.5	0
166	Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, 11012-11012.	1.6	0
167	Different Procedures Should Be on Offer. Deutsches &#x0308;rzteblatt International, 2015, 112, 175.	0.9	0
168	Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial.. Journal of Clinical Oncology, 2016, 34, 1054-1054.	1.6	0
169	ASO Visual Abstract: Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment to Reliably Exclude Residual Cancer in Breast Cancer Patients. Annals of Surgical Oncology, 2022, 29, 1085-1086.	1.5	0
170	Abstract PD7-02: Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery. Cancer Research, 2022, 82, PD7-02-PD7-02.	0.9	0
171	Abstract PD11-05: Intelligent shear-wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPIRED 002): An international, multicenter analysis. Cancer Research, 2022, 82, PD11-05-PD11-05.	0.9	0
172	Abstract P2-12-08: Impact of summation dose intensity product on pathologic response in patients receiving neoadjuvant chemotherapy for early breast cancer. Cancer Research, 2022, 82, P2-12-08-P2-12-08.	0.9	0